Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 12/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076295 | 1.00 | CHRM3 (0.76) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4636900 | 0.89 | CHRM3 (0.60) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4636555 | 0.88 | CHRM3 (0.60) | CHRM3CHRM2CHRM1 | |
| SCHEMBL141476 | 0.86 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| SCHEMBL140527 | 0.86 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL157068 | 0.85 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL541395 | 0.85 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2073894 | 0.85 | CHRM3 (0.77) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2073896 | 0.85 | CHRM3 (0.77) | CHRM3CHRM2CHRM1 | |
| SCHEMBL72305 | 0.79 | CHRM3 (0.77) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2020-03-17 | — | — | US | disclosed |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL SA (ES) | 2019-06-20 | — | — | US | disclosed |
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2018-07-31 | — | — | US | disclosed |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2017-11-09 | — | — | US | disclosed |
| US-9687478-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2017-06-27 | — | — | US | disclosed |
| US-RE46417-E1 | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands | ALMIRALL, S.A. (ES) | 2017-05-30 | — | — | US | disclosed |
| US-20160296503-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2016-10-13 | — | — | US | disclosed |
| US-9333195-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2016-05-10 | — | — | US | disclosed |
| US-20150246026-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2015-09-03 | — | — | US | disclosed |
| EP-1200431-B3 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTORS LIGANDS | ALMIRALL SA (ES) | 2015-06-24 | — | — | EP | disclosed |
| US-7196098-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL PRODESFARMA AG (CH) | 2007-03-27 | — | — | US | disclosed |
| US-7109210-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL PRODESFARMA AG (CH) | 2006-09-19 | — | — | US | disclosed |
| US-7078412-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL PRODESFARMA AG (CH) | 2006-07-18 | — | — | US | disclosed |
| US-20060106055-A1 | 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, particularly bromide or trifluoroacetate, for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-05-18 | — | — | US | disclosed |
| US-20060106056-A1 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-05-18 | — | — | US | disclosed |
| US-20050209272-A1 | 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, particularly bromide or trifluoroacetate, for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds | ALMIRALL PRODESFARMA, S.A. (ES) | 2005-09-22 | — | — | US | disclosed |
| US-20040132768-A1 | substituted with (hetero)aryl carbonyloxy group and quaternized, e.g., 3(R)-Diphenylacetoxy-1-(3-phenoxy-propyl)-1-azoniabicyclo[2.2.2]octane; bromide; antimuscarinic agents for treating COPD, chronic bronchitis, asthma and rhinitis. | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-07-08 | — | — | US | disclosed |
| US-6750226-B2 | FOR MANUFACTURE OF MEDICAMENT FOR USE IN THERAPY OF RESPIRATORY, URINARY OR GASTROINTESTINAL DISEASE | ALMIRALL-PRODESFARMA, S.A. (ES) | 2004-06-15 | — | — | US | disclosed |
| EP-1200431-B1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTORS LIGANDS | ALMIRALL PRODESFARMA AG (CH) | 2003-03-26 | — | — | EP | disclosed |
| US-20030055080-A1 | For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease | ALMIRALL, S.A. (ES) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | CHRM3 2/4885CHRM2 8/4885CHRM1 4/4885 |
| US-20060106056-A1 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | CHRM3, CHRM4, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 5/4885 |
| US-20160296503-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO2, CHRM3 | CHRM3 3/4885CHRM2 11/4885CHRM1 8/4885 |
| US-20040132768-A1 | substituted with (hetero)aryl carbonyloxy group and quaternized, e.g., 3(R)-Diphenylacetoxy-1-(3-phenoxy-propyl)-1-azoniabicyclo[2.2.2]octane; bromide; antimuscarinic agents for treating COPD, chronic bronchitis, asthma and rhinitis. | CHRM3, CBR1, CHRNB1 | CHRM3 1/4885CHRM2 5/4885CHRM1 10/4885 |
| US-20050209272-A1 | 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, particularly bromide or trifluoroacetate, for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds | NR3C2, NR3C1, NR4A3 | CHRM3 9/4885CHRM2 30/4885CHRM1 64/4885 |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRNB1, ARRB1 | CHRM3 1/4885CHRM2 4/4885CHRM1 5/4885 |
| US-20030055080-A1 | For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease | NR1H4, CHRM3, CHRM4 | CHRM3 2/4885CHRM2 8/4885CHRM1 11/4885 |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | CHRM3 2/4885CHRM2 10/4885CHRM1 7/4885 |
| US-20150246026-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | NR4A1, CHRM4, NR4A3 | CHRM3 10/4885CHRM2 11/4885CHRM1 21/4885 |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | CHRM3, QDPR, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 8/4885 |
| US-20060106055-A1 | 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, particularly bromide or trifluoroacetate, for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds | NR3C2, NR3C1, NR4A3 | CHRM3 7/4885CHRM2 23/4885CHRM1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.